Investigating risk factors for disability progression in Multiple Sclerosis
Official title: Investigating the Longitudinal Relationships Between Visual Pathway Injury, Radiological and Blood Biomarkers in Multiple Sclerosis and Related Disorders
Run by Cedars-Sinai Medical Center · NCT05204459 · Data updated 2026-11-12
This study is trying to find out what factors might make disability get worse in people with Multiple Sclerosis by looking at their medical history and MRI scans.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Cedars-Sinai Medical Center Academic / other |
| Locations | 1 site (Los Angeles, California) |
| Status | Recruiting |
| Started | November 11, 2021 |
| Main results expected | November 11, 2041 |
| Study ends | November 11, 2041 |
| Registry record updated | February 6, 2024 |
| Trial ID | NCT05204459 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with a diagnosis of Multiple Sclerosis, Clinically Isolated Syndrome, or related neurological disorders.
✕Probably not a fit
Patients with contraindications to MRI or those who are pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to identify risk factors that contribute to disability progression in Multiple Sclerosis and related disorders. Participants will undergo a comprehensive screening process at Cedars-Sinai Medical Center, where their medical and MRI records will be reviewed to determine eligibility. The main research will involve collecting demographic data, medical history, and conducting quantitative disability assessments, alongside optional sub-studies that may include blood draws and additional MRI scans. The study will utilize historical and ongoing MRI data to predict changes in disability measures.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction of disability progression in patients with Multiple Sclerosis, allowing for better management and treatment strategies.
How similar studies have gone: Other studies have shown promise in using MRI and biomarker data to assess disability progression in Multiple Sclerosis, indicating that this approach is supported by previous research.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects who meet any one of the following diagnostic criteria: * Diagnosis of MS, CIS,or RIS based on the 2017 revised McDonald criteria. * Diagnosis of NMOSD based on the 2015 revised NMOSD consensus diagnostic criteria. * Diagnosis of myelin oligodendrocyte glycoprotein (MOG)-related encephalomyelitis, optic neuritis, or other associated disease. * Diagnosis of neurological disorders other than MSRD. * Healthy volunteer. * Age ≥18. * Able to give informed consent. Exclusion Criteria: * Patients will be excluded from the MRI portions of the study if they have a contraindication to MRI(metallic implantsor foreign bodies, claustrophobia, MRI-incompatible pacemakers, MRI- incompatible prosthetic heart valves). * Patients will be excluded from the MRI portions of the study if they are pregnant, but their demographic, clinical information,and disability measures may still be captured under the study. * Patients will be excluded from the visual assessment portions of the study if they have had any recent ocular surgery (within the past two months), refractive errors of greater than or equal to ±6 diopters or other eye diseases that may affect or confound OCT/OCTA measurements (ex., age-related macular degeneration, advanced geographic atrophy, diabetic retinopathy, glaucoma).
Where it's running
-
Cedars-Sinai Medical Center
Los Angeles, California, United States Recruiting
Study contacts
- Principal investigator: Omar Al-Louzi, MD — Cedars-Sinai Medical Center
- Study coordinator: Omar Al-Louzi, MD
- Email: omar.allouzi@cshs.org
- Phone: (310) 423-4008
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational study of patients with Multiple Sclerosis in Switzerland
This study is trying to find out more about the early signs of Multiple Sclerosis and how it changes over time by looking at health data from patients in Switzerland.
-
AI-assisted care for Multiple Sclerosis
This study is testing whether using AI can help doctors better diagnose and treat people with Multiple Sclerosis by analyzing real-world data.
-
Using ultra-high field and metabolic MRI to understand resilience and degeneration in the aging and diseased brain
This project will try advanced 3T and 7T MRI scans, including sodium and phosphorus imaging, to see if metabolic and connectivity changes explain resilience and degeneration in adults with MS, NMOSD, MOGAD, Alzheimer’s, Parkinson’s, or healthy aging.
-
Observational study on CNS inflammatory demyelinating diseases in the Chinese population
This study is looking to understand how certain brain diseases, like Multiple Sclerosis, affect people in China and what factors might influence their progression and treatment.
-
Brief low-oxygen breathing to boost nerve plasticity and arm strength in MS
This will see if brief bouts of low-oxygen breathing (acute intermittent hypoxia) can quickly improve arm and hand strength and nerve signaling in people with relapsing-remitting MS who have arm weakness.
-
Breathing low oxygen levels to improve strength in people with multiple sclerosis
This study is testing if short periods of low oxygen can help people with multiple sclerosis get stronger and improve their brain's ability to control movement.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.